Jade Biosciences, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Jade Biosciences, Inc. (JBIO) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $5.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-10
- Jade Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $84.00K, a 98.25% decline year-over-year.
- Jade Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $5.77M.
- Jade Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$3.50M, a 193.58% decline year-over-year.
- Jade Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $4.58M, a 1776.23% increase year-over-year.
- Jade Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $3.94M.
- Jade Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$9.91M, a 199.14% decline from fiscal 2023.
- Jade Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $10.00M, a 172.30% increase from fiscal 2022.
- Jade Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $3.67M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 0 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $5.86M 10-Q · filed 2026-08-10 | $2.36M derived: sum of 3 quarters · filed 2026-08-10 | $6.94M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $5.77M 10-Q · filed 2026-05-07 | $2.28M derived: sum of 2 quarters · filed 2026-05-07 | $6.85M derived: sum of 3 quarters · filed 2026-05-07 | $11.66M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $1.08M derived: sum of 2 quarters · filed 2026-03-06 | $5.89M derived: sum of 3 quarters · filed 2026-08-10 | $3.94M 10-K · filed 2026-03-06 | ||
| 2025-09-30 | $4.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $9.39M derived: sum of 2 quarters · filed 2026-08-10 | $7.44M 10-Q · filed 2025-11-14 | $11.18M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $4.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.86M 10-Q · filed 2026-08-10 | $6.60M derived: sum of 3 quarters · filed 2026-08-10 | $6.84M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | -$1.95M 10-Q · filed 2026-05-07 | -$1.15M 10-Q · filed 2025-04-25 | $1.79M derived: sum of 2 quarters · filed 2026-05-07 | $2.03M derived: sum of 3 quarters · filed 2026-05-07 | $2.64M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $3.74M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | $3.98M 10-K · filed 2026-03-06 | $4.59M derived: sum of 3 quarters · filed 2026-03-06 | -$9.91M 10-K · filed 2025-03-27 | ||
| 2024-09-30 | $244.00K 10-Q · filed 2025-11-14 | $850.00K derived: sum of 2 quarters · filed 2025-11-14 | -$4.15M 10-Q · filed 2024-11-12 | $1.84M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $590.00K 10-Q · filed 2025-08-13 | $606.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$2.46M 10-Q · filed 2024-08-12 | $1.60M derived: sum of 3 quarters · filed 2025-04-25 | $4.99M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | -$3.06M 10-Q · filed 2025-04-25 | $990.00K derived: sum of 2 quarters · filed 2025-04-25 | $4.38M derived: sum of 3 quarters · filed 2025-04-25 | $6.22M derived: sum of 4 quarters · filed 2025-04-25 | ||
| 2023-12-31 | $4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $7.45M derived: sum of 2 quarters · filed 2025-03-27 | $9.28M derived: sum of 3 quarters · filed 2025-03-27 | $10.00M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $3.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.23M derived: sum of 2 quarters · filed 2024-11-12 | $5.95M 10-Q · filed 2024-11-12 | $7.99M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.55M 10-Q · filed 2024-08-12 | $4.59M derived: sum of 3 quarters · filed 2024-08-12 | $6.04M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $716.00K 10-Q · filed 2024-05-13 | $2.75M derived: sum of 2 quarters · filed 2024-05-13 | $4.20M derived: sum of 3 quarters · filed 2024-05-13 | $3.89M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $3.48M derived: sum of 2 quarters · filed 2024-03-25 | $3.17M derived: sum of 3 quarters · filed 2024-03-25 | $3.67M 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.14M derived: sum of 2 quarters · filed 2023-11-13 | $1.64M 10-Q · filed 2023-11-13 | $1.66M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | -$306.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $191.00K 10-Q · filed 2023-08-14 | $218.00K derived: sum of 3 quarters · filed 2023-08-14 | $190.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $497.00K 10-Q · filed 2023-05-15 | $524.00K derived: sum of 2 quarters · filed 2023-05-15 | $496.00K derived: sum of 3 quarters · filed 2023-05-15 | $1.42M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$1.00K derived: sum of 2 quarters · filed 2023-03-29 | $918.00K derived: sum of 3 quarters · filed 2023-03-29 | -$6.00K 10-K · filed 2023-03-29 | ||
| 2021-09-30 | -$28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $891.00K derived: sum of 2 quarters · filed 2022-11-14 | -$33.00K 10-Q · filed 2022-11-14 | $585.00K derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $919.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$5.00K 10-Q · filed 2022-08-15 | $613.00K derived: sum of 3 quarters · filed 2022-08-15 | $734.00K derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | -$924.00K 10-Q · filed 2022-05-16 | -$306.00K derived: sum of 2 quarters · filed 2022-05-16 | -$185.00K derived: sum of 3 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $618.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $739.00K derived: sum of 2 quarters · filed 2022-03-30 | $1.04M 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $422.00K 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $301.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |